To observe the sedative effect and safety of remiazolam combined with small dose of esketamine in painless bidirectional endoscopy in children, and to provide a more reasonable and safe sedative and analgesic regimen for children's gastrointestinal endoscopy.

It is planned to observe the painless two-way endoscopic examination of children in Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology from November 2022 to May 2023.To observe the sedative effect and safety of remiazolam combined with small dose of esketamine in painless bidirectional endoscopy in children, and to provide a more reasonable and safe sedative and analgesic regimen for children's gastrointestinal endoscopy.

Inclusion Criteria:

• Age 0-17;
• ASA Class I-II;
• Sign the informed consent form.

Exclusion Criteria:

• Patients with high risk of stomach satiety and reflux aspiration;
• Patients allergic to the study drug;
• Obesity or severe malnutrition;
• Those who have taken sedative, analgesic or antidepressant drugs within 24 hours;
• Hypertension without treatment;
• Abnormal liver and kidney function (index ≥ 2 times the upper limit of normal reference range);
• Other congenital diseases or acute and chronic diseases that affect the observation of curative effect;
• Participate in other clinical studies within 4 weeks.

Research data can be requested from the main researchers via email

Since propofol is white uniform emulsion, and ramazolam is colorless, clear and transparent liquid, anesthesiologists and surgeons may see the color of the study drug during operation, so this study is a single blind clinical study